October 19th, 2026New CHEST Guidelines Offer a Road Map for BronchiectasisSpeakers at CHEST 2026 walked through the first CHEST guideline for non-CF adult bronchiectasis, including which preventive therapy to start first.Read more
October 19th, 2026FDA Approves Ryzumvi for Presbyopia, Expanding Its LabelPhentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.Read more
October 19th, 2026FDA Approves First At-Home Subcutaneous Thyroid Eye Disease TreatmentSatralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.Read more
October 19th, 2026AAO 2026: Closing the Screening Gap in Diabetic RetinopathyThe meeting covered several topics in eye care, including how artificial intelligence (AI) can play a part in eye care.Read more
October 19th, 2026Higher Platelet-to-Neutrophil Ratio Linked With Lower MASLD OddsA higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.Read more
October 17th, 2026Automated HCV Surveillance Shows Promise But Needs ValidationSaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.Read more
October 16th, 2026Genetic Analysis Links Insomnia Liability to Higher Inflammation MarkerGenetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.Read more
October 16th, 2026Proinflammatory Diets Linked to Higher MASLD, MetALD MortalityProinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.Read more